[1]赵东婷,韩萍*,肖远革,等.药物治疗对高危型人乳头瘤病毒感染的转归及 白细胞介素-4变化的研究[J].中国计划生育和妇产科,2018,(6):31-34.
　ZHAO Dong-ting,HAN Ping*,XIAO Yuan-ge,et al.Study on the clinical effect of drug treatment for high-risk HPV infection and the change of IL-4[J].Chinese Journal of Family Planning & Gynecotokology,2018,(6):31-34.
点击复制

药物治疗对高危型人乳头瘤病毒感染的转归及 白细胞介素-4变化的研究
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年6期
页码:
31-34
栏目:
论著与临床
出版日期:
2018-06-25

文章信息/Info

Title:
Study on the clinical effect of drug treatment for high-risk HPV infection and the change of IL-4
作者:
赵东婷; 韩萍*; 肖远革; 刘聪慧; 张韦; 何艳舫; 丁霄
华北理工大学附属医院妇产科
Author(s):
ZHAO Dong-ting; HAN Ping*;  XIAO Yuan-ge;  LIU Cong-hui; ZHANG Wei; HE Yan-fang; DING Xiao
Department of Gynecology and Obstetrics,North China University of Science and Technology Affiliated Hospital,Tangshan Hebei 063000,P.R.China
关键词:
宫颈病变; HPV;  IL-4
Keywords:
cervical lesions;  HPV; IL-4
分类号:
R 73733
摘要:
目的探讨药物治疗高危人乳头瘤病毒(high-risk human papillomavirus，HR-HPV)感染的临床疗效及阴道局部免疫功能的变化。方法选取2015~2017年在华北理工大学附属医院就诊的78例HR-HPV感染并经活检病理确诊为低级别鳞状上皮内病变或炎症的患者为研究对象。按照随机数字表法分为3组，第1组患者（28）例不使用任何药物治疗；第2组患者（30例）给予抗HPV生物蛋白敷料治疗；第3组患者（20例）给予红色诺卡氏菌细胞壁骨架治疗。所有患者入组后第3个月复查HPV及液基细胞学检查，观察患者HPV转归情况，且取患者在治疗前及治疗后的阴道灌洗液，行白细胞介素（interleukin, IL）-4的测定，观察患者阴道免疫功能的变化。结果3组患者治疗3个月后，各组清除HPV感染有效率（1786 %、7333 %、45 %）比较，差异有统计学意义（P＜005）。治疗前后IL-4的OD差值［（589±11107）pg/mL、（2103±19477）pg/mL、（1587±17427）pg/mL］，第1组OD值与其它两组比较差异有统计学意义（P＜005），第2组与第3组比较差异无统计学意义（P＞005）。结论 药物治疗对HR-HPV感染临床有效，在随访3个月时抗HPV生物蛋白敷料效果更明显。药物治疗可以改善阴道微环境，提高机体局部免疫力。
Abstract:
ObjectiveTo investigate the clinical effects of drug treatment of high -risk human papillomavirus (HR-HPV) infection and the changes of vaginal local immune function. Methods78 patients with HR-HPV positive and biopsy pathology diagnosed as low-grade squamous intraepithelial lesion or inflammation in North China University of Science and Technology Affiliated Hospital from 2015 to 2017 were entrolled in the study. All were divided into 3 groups acconling to the random number table methad, including 28 cases had no operation,30 cases who accepted anti-HPV biological dressing（JB01-BD）treatment,20 cases accepted nocadia rubra cell wall skeleton for external use(Nr-CWS) treatment.HPV and TCT were tested after 3 months, the effect on HPV were observed between three groups.And take the vaginal lavage fluid before and after treatment,detect IL-4 to observe the changes of vaginal immune fuction. ResultsThe effective remova rates of HR-HPV in the three groups were 1786 %，7333 % and 45 %, the differences among the groups were statistically significant(P<005). The differences of IL-4 OD value before and after treatment in the theree groups were（589±11107）pg/mL,(2103±19477) pg/mL and (1587±17427)pg/mL.There were significant differences between the first group and the other two groups(P<005).There was no significant difference between the second group and the third group(P>005).ConclusionDrug treatment is clinically effective for HR-HPV infection anti-HPV biological dressing promoted the regression of cervical lesions as well as accelerated the clearance of HR-HPV after cervieal conization therapy.

参考文献/References:

［1］刘安丽，贺生．高危型HPV原位杂交检测和P 53、Ki-67在宫颈鳞癌及子宫颈上皮内瘤变组织中的表达及意义 ［J］．中国妇幼保健，2012，27（29）：4611-4614． ［2］MAGLENNON G A, DOORBAR J The biology of papillomavirus latency ［J］ The Open Virology Journal, 2012, 6: 190-197. ［3］罗汝琼，唐亮．HR-HPV在宫颈病变中的表达及不同治疗方法的转阴率分析 ［J］．中国妇幼健康研究，2016，27（8）：1018-1021． ［4］王伯红，吴兵．人乳头状瘤病毒与生殖系统常见病原体感染的相关性分析 ［J］．中国妇幼保健，2013，28（5）：809-812． ［5］NGUYEN M L, FLOWERS L. Cervical cancer screening in immunocompromised women ［J］. Obstetrics and Gynecology Clinics of North America, 2013, 40(2): 339-357. ［6］VACCINATION H P. Committee Opinion No.641.American College of Obstetricians and Gynecologists ［J］. Obstetrics and Gynecology, 2015, 126(3): e38-e43. ［7］MASSAD L S, EINSTEIN M H, HUH W K, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors ［J］. Journal of Lower Genital Tract Disease, 2013, 17(5 suppl 1): S1-S27.

相似文献/References:

[1]彭丽霞,张娟.阴道镜下定位活检在宫颈病变诊断中的价值[J].中国计划生育和妇产科,2009,(06):0.
　PENG Li-xia,ZHANG Juan.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(6):0.
[2]陶凤喜,王海新.HPV感染与宫颈病变的关系分析[J].中国计划生育和妇产科,2010,(05):0.
　TAO Feng-xi,WANG Hai-xin.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[3]罗海全,李明,刘兴会,等.宫颈病变锥形切除术后妊娠不良结局相关因素分析[J].中国计划生育和妇产科,2010,(05):0.
　LUO Hai-quan,LI Ming,LIU Xing-hui ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[4]普俊梅,文勇,黄予,等.高危型HPV DNA检测在宫颈病变筛查和宫颈癌预防中的价值[J].中国计划生育和妇产科,2012,(04):0.
　PU Jun-mei,WEN Yong,HUANG Yu,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[5]孟跃进,顾晓荔.阴道镜宫颈病变活体组织检查及活体组织检查后治疗问题[J].中国计划生育和妇产科,2013,(01):0.
　MENG Yue-jin,GU Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[6]张宏伟,隋龙.液基细胞学技术在宫颈病变筛查的应用现状及不足[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Hong-wei,SUI Long Medical Center of Diagnostics & Treat for Cervical Disease,Gynaecology and Obstetrics Hospital of Fudan University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[7]张翼婷,王晓玉,罗新,等.初善仪子宫颈癌筛查系统在宫颈病变筛查中的应用[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Yi-ting,WANG Xiao-yu*,LUO Xin.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[8]陈志龙,史惠蓉.人乳头状瘤病毒L1蛋白在宫颈病变中的表达及其意义[J].中国计划生育和妇产科,2013,(01):0.
　CHEN Zhi-long,SHI Hui-rong*.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[9]吴晓菁,谈军,李优云,等.广州市白云区流动人口育龄妇女HPV感染及宫颈病变的流行病学调查[J].中国计划生育和妇产科,2013,(03):0.
　WU Xiao - jing,TAN Jun,LI You - yun,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[10]安红梅,张雯,邓继红,等.昆明地区高危HPV病毒载量与宫颈病变和宫颈癌相关性[J].中国计划生育和妇产科,2013,(03):0.
　AN Hong - mei,ZHANG Wen,DENG Ji - hong *,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.

更新日期/Last Update: 2018-06-25